ClinicalTrials.gg
RecruitingNCT07309783Updated Jul 9, 2026

Lung EIT Image Guide Ventilation in ARDS

An interventional study of Recruitment maneuver and PEEP setting guided by EIT and PEEP setting according to routine practice in ARDS (Acute Respiratory Distress Syndrome), sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
574
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Acute Lung Injury with a site in China — 20 open to participants now, 20 under way, 1 of them phase 3. Acute Lung Injury · China.

Planned enrollment
2nd of 31
574 · median 60
Started
2026
with 7 others
No phase
20 of 59
6 open now
Primary completion
2028-12
later than 18 of 19 live
Registered
52nd of 59
by date
Lead sponsor
7 of 59
Peking Union Medical College Hospital

Among the 59 studies in Acute Lung Injury with a site in China, this one is the 2nd largest by planned enrollment of the 31 interventional ones that give a count, is one of 8 that started in 2026, is one of 20 with no phase, reaches primary completion later than 18 of the 19 other live ones, and was the 52nd registered.

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

Browse Acute Lung Injury studies →

Open to participants now

20 of the 59 studies in Acute Lung Injury with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Acute Lung Injury with a site in China, or all of them as a file.
02

Study summary

The goal of this multi-center randomized controlled clinical trial is to learn if an individualized, bedside electrical impedance tomography (EIT)-guided ventilation strategy (including EIT-guided prone positioning and PEEP titration) can improve outcomes compared with a conventional lung-protective ventilation strategy in adult patients with acute respiratory distress syndrome (ARDS).

The main questions it aims to answer are:

Does the individualized EIT-guided ventilation strategy reduce 28-day mortality in ARDS patients? Researchers will compare the EIT-guided intervention arm to a control arm receiving routine lung-protective ventilation (without bedside EIT guidance) to see if the EIT-guided approach lowers 28-day mortality and improves other clinical outcomes.

Adult ARDS patients who meet inclusion criteria will be assigned to EIT-guided group and control group through stratified randomization:

EIT-guided group: Undergo bedside EIT assessments using a China-manufactured EIT device to guide decisions about prone positioning and individualized PEEP titration (including a recruitment maneuver).

Control group: Receive PEEP setting per conventional PEEP-FiO₂ tables and prone positioning per standard clinical indications without EIT guidance.

Both groups: Receive standard supportive ICU care and routine outcome assessments at multiple time points.

Primary outcome: 28-day mortality. Other outcomes include ventilator-free days to day 28 and so on.

03

Conditions studied

  • ARDS (Acute Respiratory Distress Syndrome)

Browse trials for

Keywords

  • ARDS
  • EIT-guided ventilation strategy
  • EIT-guided prone positioning
  • EIT-guided PEEP setting
  • RCT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with ARDS receiving mechanical ventilation who meet the following diagnostic criteria:

    1. Triggered by acute risk factors such as pneumonia, non-pulmonary infection, trauma, transfusion, aspiration, or shock. Pulmonary edema is not entirely or predominantly attributable to cardiogenic causes or fluid overload, and hypoxemia/gas exchange impairment is not mainly due to atelectasis. However, ARDS can be diagnosed in the presence of these conditions if predisposing risk factors exist.
    2. Acute onset or worsening of hypoxemic respiratory failure within 1 week of the identified risk factor or onset of new or worsening respiratory symptoms.
    3. Bilateral opacities on chest radiograph or CT, or bilateral B-lines and/or consolidation on ultrasound, not fully explained by effusion, atelectasis, or nodules/masses.
    4. PaO₂/FiO₂ ≤ 300 mm Hg or SpO₂/FiO₂ ≤ 315 (if SpO₂ ≤ 97%).
  • ARDS onset within 1 week.
  • Mechanical ventilation ≤ 72 hours.

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years.
  • Pregnancy.
  • to EIT application (e.g., local skin lesions, cardiac pacemaker).
  • Contraindications to prone positioning (e.g., increased intracranial pressure, intra-abdominal hypertension, spinal fractures).
  • Evidence of barotrauma such as pneumothorax, mediastinal emphysema, or subcutaneous emphysema.
  • End-stage disease.
  • not signed by legal guardians or family.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
574 participants (estimated)

Study arms

  • Experimental
    EIT-guided group

    Prone positioning and PEEP titration guided by China-manufactured EIT.

    Other: Recruitment maneuver and PEEP setting guided by EIT · Behavioral: Prone positioning guided by EIT

  • Active comparator
    Control group

    PEEP set guided by conventional PEEP-FiO₂ table and prone positioning guided by routine clinical indications without EIT guidance.

    Other: PEEP setting according to routine practice · Behavioral: Prone positioning according to routine practice

Interventions

  • OtherRecruitment maneuver and PEEP setting guided by EIT

    The EIT-guided group, will receive recruitment maneuver and PEEP titration guided by EIT to determine the optimal PEEP level.

  • OtherPEEP setting according to routine practice

    The control group will receive routine ventilation strategy. Routine recruitment maneuver is not recommended but may be used as rescue therapy. PEEP is set using the conventional PEEP-FiO₂ table.

  • BehavioralProne positioning guided by EIT

    The EIT-guided group, will determine prone positioning therapy based on EIT.

  • BehavioralProne positioning according to routine practice

    The control group will determine prone positioning therapy based on routine practice.

06

What researchers measure

Primary outcomes

  1. 28-day mortality

    The survival status on the 28th day after randomization

    Time frame: Day 28 after randomization

Secondary outcomes

  1. Ventilator-free days within 28 days after randomization

    Ventilator-free days within 28 days after randomization

    Time frame: within 28 days after randomization

  2. Ventilator-free days within 14 days after randomization

    Ventilator-free days within 14 days after randomization

    Time frame: Within 14 days after randomization

07

Study locations

1 of 1 sites recruiting
  • Department of Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100730, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 32 months after the start.

Of 51 non-industry interventional studies with no phase under Acute Lung Injury, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 34. This study's planned 32 months is above that.

Counting every sponsor, half of 52 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 30, 2025
StartActual
Mar 24, 2026
Primary completionEst.
Dec 20, 2028
CompletionEst.
Jun 20, 2029
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07309783
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Mar 24, 2026
Primary completion
Dec 20, 2028 (estimated)
Completion
Jun 20, 2029 (estimated)
Last update
Jul 9, 2026

Study contacts

Huaiwu He, MD
Contact
tjmuhhw@163.com
86-010-69152300
Siyi Yuan, MD
Contact
yuansiyi@pumch.cn
86-010-69152300
Huaiwu He, MD
study chair · Department of Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion